Anthony K C Chan1, James M Mason2, Minas Baltatzis1, Ajith K Siriwardena3,4. 1. Regional Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Manchester, UK. 2. Warwick Medical School, The University of Warwick, Coventry, UK. 3. Regional Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Manchester, UK. ajith.siriwardena@mft.nhs.uk. 4. Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. ajith.siriwardena@mft.nhs.uk.
Abstract
BACKGROUND: Approximately one-fifth of patients with colorectal cancer present with hepatic metastases. There are limited prospective data on the outcomes of synchronous combined liver and bowel surgery and liver-first or bowel-first routes where contemporary chemo(radio)therapy is integrated into management. METHODS: Between 1 April 2014 and 31 March 2017, 125 patients with colorectal cancer and synchronous liver metastases were recruited. Data are reported on pathway-specific outcomes, including perioperative complications, treatment completion, and overall and disease-free survival. The study was registered with ClinicalTrials.gov (NCT02456285). RESULTS: There was no difference in age, body mass index, or Charlson score between surgical groups. Neoadjuvant chemotherapy was used in 50 (40%) patients for a mean duration of 4.6 months (standard deviation [SD] 5.4), and mean time from completion of chemotherapy to surgery was 2.6 months (SD 1.9). Complications were similar between patients completing the synchronous and staged pathways (p = 0.66). Mean total inpatient stay was 16.5 days (SD 8.1) for staged surgery compared with 16.8 days (SD 10.3) for the synchronous group (t-test; p = 0.91). There was no difference in time to treatment completion between pathways. Thirty six (35%) patients were disease-free at 12 months, with no significant difference between groups (Chi-square, p = 0.448). Quality of life was similar in all surgical groups. CONCLUSIONS: Perioperative complications and oncological and healthcare occupancy outcomes are equivalent between patients completing staged and synchronous pathways for the management of patients with colorectal cancer and synchronous liver metastases. Future studies should focus on optimizing the criteria for pathway selection, incorporation of cancer genomics data, and patient (user) preferences.
BACKGROUND: Approximately one-fifth of patients with colorectal cancer present with hepatic metastases. There are limited prospective data on the outcomes of synchronous combined liver and bowel surgery and liver-first or bowel-first routes where contemporary chemo(radio)therapy is integrated into management. METHODS: Between 1 April 2014 and 31 March 2017, 125 patients with colorectal cancer and synchronous liver metastases were recruited. Data are reported on pathway-specific outcomes, including perioperative complications, treatment completion, and overall and disease-free survival. The study was registered with ClinicalTrials.gov (NCT02456285). RESULTS: There was no difference in age, body mass index, or Charlson score between surgical groups. Neoadjuvant chemotherapy was used in 50 (40%) patients for a mean duration of 4.6 months (standard deviation [SD] 5.4), and mean time from completion of chemotherapy to surgery was 2.6 months (SD 1.9). Complications were similar between patients completing the synchronous and staged pathways (p = 0.66). Mean total inpatient stay was 16.5 days (SD 8.1) for staged surgery compared with 16.8 days (SD 10.3) for the synchronous group (t-test; p = 0.91). There was no difference in time to treatment completion between pathways. Thirty six (35%) patients were disease-free at 12 months, with no significant difference between groups (Chi-square, p = 0.448). Quality of life was similar in all surgical groups. CONCLUSIONS: Perioperative complications and oncological and healthcare occupancy outcomes are equivalent between patients completing staged and synchronous pathways for the management of patients with colorectal cancer and synchronous liver metastases. Future studies should focus on optimizing the criteria for pathway selection, incorporation of cancer genomics data, and patient (user) preferences.
Authors: L Weiss; E Grundmann; J Torhorst; F Hartveit; I Moberg; M Eder; C M Fenoglio-Preiser; J Napier; C H Horne; M J Lopez Journal: J Pathol Date: 1986-11 Impact factor: 7.996
Authors: Povilas Ignatavicius; Christian E Oberkofler; William C Chapman; Ronald P DeMatteo; Bryan M Clary; Michael I D'Angelica; Kenneth K Tanabe; Johnny C Hong; Thomas A Aloia; Timothy M Pawlik; Roberto Hernandez-Alejandro; Shimul A Shah; Jean-Nicolas Vauthey; Guido Torzilli; Hauke Lang; Pål-Dag Line; Olivier Soubrane; Hugo Pinto-Marques; Ricardo Robles-Campos; Karim Boudjema; Peter Lodge; René Adam; Christian Toso; Alejandro Serrablo; Luca Aldrighetti; Michelle L DeOliveira; Philipp Dutkowski; Henrik Petrowsky; Michael Linecker; Cäcilia S Reiner; Julia Braun; Ruslan Alikhanov; Giedrius Barauskas; Albert C Y Chan; Jiahong Dong; Norihiro Kokudo; Masakazu Yamamoto; Koo Jeong Kang; Yuman Fong; Mohamed Rela; Xabier De Aretxabala; Eduardo De Santibañes; Miguel Ángel Mercado; Oscar C Andriani; Orlando Jorge M Torres; Antonio D Pinna; Pierre-Alain Clavien Journal: Ann Surg Date: 2020-11 Impact factor: 12.969
Authors: H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes Journal: Ann Oncol Date: 2012-10 Impact factor: 32.976
Authors: René Adam; Aimery De Gramont; Joan Figueras; Ashley Guthrie; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Josep Tabernero; Catherine Teh; Eric Van Cutsem Journal: Oncologist Date: 2012-09-07
Authors: René Adam; Aimery de Gramont; Joan Figueras; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Catherine Teh; Sabine Tejpar; Eric Van Cutsem; Jean-Nicolas Vauthey; Lars Påhlman Journal: Cancer Treat Rev Date: 2015-06-30 Impact factor: 12.111
Authors: Ajith K Siriwardena; James M Mason; Saifee Mullamitha; Helen C Hancock; Santhalingam Jegatheeswaran Journal: Nat Rev Clin Oncol Date: 2014-06-03 Impact factor: 66.675
Authors: Robert P Jones; Norihiro Kokudo; Gunnar Folprecht; Yoshihiro Mise; Michiaki Unno; Hassan Z Malik; Stephen W Fenwick; Graeme J Poston Journal: Liver Cancer Date: 2016-11-29 Impact factor: 11.740